Fremanezumab (AJOVY®) receives positive recommendation by NICE for chronic migraine

Written by Sharon Salt, Senior Editor

Teva Pharmaceutical Europe BV (Tel Aviv, Israel) has announced that NICE has recommended fremanezumab (AJOVY®) for the treatment of chronic migraine in adults. This recommendation is aimed towards individuals with chronic migraine who have not responded to at least three prior preventive drug treatments. Fremanezumab is a long-acting treatment indicated for the prophylaxis of migraine in adults who have at least four migraine days per month. It is available as a 225 mg/1.5 ml single dose injection in a pre-filled syringe with two dosing options available – 225 mg monthly administration as one subcutaneous injection, or 675 mg every 3...

To view this content, please register now for access

It's completely free